DBV perseveres with peanut project
DBV plans to refile Viaskin Peanut in the third quarter, but things look all but smooth.
Sanofi does a spring clean
The French company has taken a look at its R&D portfolio, and made some radical changes in oncology and diabetes.
Pharma news over the Christmas period
If the recent performance of biotech stocks prompted you to pull down the shutters until the New Year celebrations subsided here’s what you might have missed.
DBV Technologies investors go into shock with filing withdrawal
DBV Technologies’ decision to pull its Viaskin Peanut filing leaves the door open for Aimmune Therapeutics to clean up.
Most valuable unpartnered assets reveal a changing of the guard
Annual analysis shows a new crop of biotech assets with ballooning valuations and no major partners.
After Alnylam’s solo maiden launch, here comes the tricky bit
Alnylam has secured its first approval, but history suggests that launch will be far from easy.
